Meropenem Fresenius Kabi (Meropenem Anhydrous)

• Meropenem is a broad‑spectrum carbapenem used for serious bacterial infections in the hospital setting.
• Complicated intra‑abdominal infections: effective bacterial eradication in patients with intra‑abdominal sepsis.
• Complicated urinary tract infections: clears resistant uropathogens in complicated cases.
• Hospital‑acquired pneumonia: provides coverage against multidrug‑resistant organisms.
• Ventilator‑associated pneumonia: treats ventilator‑related lung infections.
• Septicemia: rapidly reduces bloodstream bacterial load.
• Other severe infections caused by susceptible bacteria: used when pathogens are known to be meropenem‑sensitive.

• Meropenem binds to penicillin‑binding proteins (PBPs) on the bacterial cell wall, inhibiting the final transpeptidation step of peptidoglycan synthesis. This disruption weakens the cell wall, leading to osmotic instability, cell lysis, and bacterial death. Its high affinity for a broad range of PBPs gives it activity against many Gram‑negative and Gram‑positive organisms, including those resistant to other β‑lactams.

Common Side Effects

• Nausea or vomiting: gastrointestinal upset occurring in many patients.
• Diarrhea: may be mild to moderate and self‑limiting.
• Rash or pruritus: skin reactions ranging from mild erythema to urticaria.
• Headache: transient headache reported during therapy.
• Elevated liver enzymes: transient increases in ALT/AST.
• Injection site phlebitis: irritation at the IV site.

Serious or Rare Side Effects

• Anaphylaxis: severe allergic reaction requiring immediate medical attention.
• Seizures: especially in patients with renal impairment or CNS disorders.
• Clostridioides difficile‑associated diarrhea: may lead to colitis.
• Renal toxicity: acute kidney injury in predisposed individuals.
• Hematologic abnormalities: thrombocytopenia or neutropenia.
• Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

• Meropenem should be used with caution in specific clinical situations.
• Renal function: adjust dose in patients with impaired renal clearance.
• Allergy: avoid in individuals with known hypersensitivity to carbapenems or β‑lactams.
• Seizure risk: monitor patients with a history of seizures or CNS disorders.
• Pregnancy: consider only if the potential benefit outweighs the risk to the fetus.
• Drug interactions: review concomitant medications for possible interactions.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Meropenem may interact with several medicines; monitoring is essential.

Major Interactions (Avoid)

• Valproic acid: meropenem reduces serum valproate levels, increasing seizure risk.
• Probenecid: may increase meropenem plasma concentrations, raising toxicity potential.
• Cytotoxic agents (e.g., cyclophosphamide): heightened neurotoxicity risk.

Moderate Interactions (Monitor Closely)

• Loop diuretics: may exacerbate renal impairment.
• Anticoagulants (warfarin): possible alteration of INR values.
• Oral contraceptives: reduced efficacy, consider alternative contraception.